Affordable Cancer Care

THERAPY PRICING, INSURANCE & COPAY
768 512 admin
  • admin
  • No Comments
  • No Likes

Session 6 – THERAPY PRICING, INSURANCE & COPAY

Session 6 started off with discussing pricing for cancer care, health insurance for cancer treatment, government policies regarding cancer care. The conclusions drawn by the panel were to train oncologists on dealing with patients in a gentler way, bring down the prices of all the various aspects of cancer care, increase insurance penetration and coverage,…

read more
PATIENT EDUCATION, ADVOCACY GROUPS & ROLE OF MEDIA
768 512 admin
  • admin
  • No Comments
  • No Likes

Session 5 – PATIENT EDUCATION, ADVOCACY GROUPS & ROLE OF MEDIA

Session 5 saw discussion of patent laws concerning pharmaceuticals, value based healthcare through prevention and product innovation, family ecosystem in cancer care, total management of cancer in all its aspects, and public-private partnerships to lead to optimum and affordable cancer care. The conclusions reached were free drugs for BPL patients, development of infrastructure in PPPs,…

read more
INDUSTRY CONCERNS AND REMEDIES
768 512 admin
  • admin
  • No Comments
  • 1 Like

Session 4 – EARLY STANDARD CURRENT DIAGNOSTICS

Session 4 opens with various modalities available for cancer diagnosis, their status, the affordability, the chances of early diagnosis with these modalities, and using out-of-the-box ideas to deal with these issues. Keeping all this in mind, we concluded that early diagnosis and screening techniques should be used in a more widespread fashion, spreading awareness and…

read more
INDIGENOUS RESEARCH & DEVELOPMENT
768 512 admin
  • admin
  • No Comments
  • 1 Like

Session 3 – INDIGENOUS RESEARCH & DEVELOPMENT

Session 3 starts with the valid points concerning lack of research in the field of cancer care: lack of money, manpower, and time, leading to very little research. Next point brought forward was public-private partnership leading to the reduction of cancer burden with the last speaker talking about a new model to provide highly subsidized…

read more
ACCI 2017 Session 2
768 512 admin
  • admin
  • No Comments
  • 1 Like

Session 2 – INDUSTRY CONCERNS AND REMEDIES

Session 2 brought up the points of the taxes being levied on machines used in cancer care, manufacturing outside India leading to increased cost of machines, orphan drug relevance and the requirement of biosimilars. The conclusion reached was that taxation on the machines should be reduced or removed, manufacture of those machines should move to…

read more

ACCI2017-All rights reserved

Enter your
text here